Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women
- Conditions
- PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 183
- Registration Number
- NCT06486870
- Locations
- 🇪🇬
faculty of medicine, Kasr el ainy hospital, Cairo university, Cairo, Egypt
A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 118
- Registration Number
- NCT06465368
- Locations
- 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇨🇳Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Letrozole and Misoprostol for Early Pregnancy Loss Management
- Conditions
- Miscarriage in First TrimesterEarly Pregnancy LossMiscarriage
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 30
- Registration Number
- NCT06452719
- Locations
- 🇺🇸
PEACE / Penn Medicine, Philadelphia, Pennsylvania, United States
Sequential Letrozole and Methotrexate Therapy Role in Treatment of Tubal Ectopic Pregnancy
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Zagazig University
- Target Recruit Count
- 200
- Registration Number
- NCT06426979
- Locations
- 🇪🇬
Zagazig university, Zagazig, Ash Sharqia Governorate, Egypt
Effect of ALA Combined with Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females
- Conditions
- Infertility, FemalePolycystic Ovary Syndrome
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 150
- Registration Number
- NCT06418347
- Locations
- 🇪🇬
Ain shams university, Cairo, Egypt
Only Gonadotropin Vs. Letrozole Combined Gonadotropin Stimulation in IUI Cycles
- Conditions
- Infertility Unexplained
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Uludag University
- Target Recruit Count
- 131
- Registration Number
- NCT06413771
- Locations
- 🇹🇷
Uludag University Faculty of Medicine, Bursa, Gorukle, Turkey
Letrozole Dose Increments in PCOS Patients Resistant to Letrozole
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 102
- Registration Number
- NCT06403488
- Locations
- 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Egypt
Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome
- Conditions
- Polycystic Ovary
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 500
- Registration Number
- NCT06405178
- Locations
- 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Egypt
Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 100
- Registration Number
- NCT06405243
- Locations
- 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Egypt
🇪🇬Beni-suef university, Banī Suwayf, Egypt
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
- Conditions
- Low-Grade Serous Ovarian Cancer
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06394804
- Locations
- 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.